Surgical Division is global leader in surgical laser technology and medical laser equipment, and considered a pioneer in the field of laser for surgery
X
GO

MOSES
TECHNOLOGY

A patent-protected innovation revolutionizing urology care

Understanding the challenges of laser lithotripsy

While Holmium lithotripsy is well established as the preferred treatment for urinary stones2, some challenges still persist:

Reduced energy transmission

Holmium’s high level of absorption in water results in limited delivery of laser energy.

Unfriendly and costly fiber experience

Burdensome and time consuming process of fiber insertion through a flexible scope is needed to avoid scope damage.

Retropulsion and stone migration

The retropulsion effect created by the Holmium pulse reduces physician’s control and may cause the stone to rotate or slip to difficult locations.

Limited access

Stones are often located in hard-to-access areas within the kidney, making it difficult to reach and treat them.


Introducing Moses™ technology by Lumenis

A patent-protected combination of systems and fibers – reframing the laws of physics

Ultra Speed Stone-Dusting for Flexible Laser Ureteroscopy

Experience optimized energy transmission

MOSES is a groundbreaking, patent-protected pulse delivery technology, that remarkably improves energy transmission, resulting in more efficient lithotripsy and BPH treatments compared to the regular Holmium pulse1

Energy transmission vs. working distance - bench test7. A representative case


MOSES Technology: 360˚ advantages for Holmium Laser Lithotripsy

20% Reduction in procedure time

As shown in a randomized clinical trial, the MOSES Technology reduces
procedure time by 20%, making your treatments faster and more efficient1,2.

60% reduction in retropulsion

With 60% less retropulsion, you can minimize the incidents of ureteral stone migration into the kidney.
You may also avoid chasing the stones in the bladder or kidney1,2,3.

25% reduction in fragmentation time

MOSES optimized energy transmission makes every shot count, thus reducing your fragmentation time by 25% 1,2.


Smooth process - more confidence

Advanced ball-shaped tip enables a smooth initial insertion of the Moses 200 D/F/L through a flexible scope, and designed to minimize potential scope damage.reach difficult-to-access stone locations.

Leave no stone behind

Moses 200 D/F/L flexible fiber is designed to minimize scope deflection loss7, allowing to reach difficult-to-access stone locations.

Deflection loss of flexible scope - bench test7. A representative case


“When compared with regular holmium laser, MOSES Technology resulted in significantly shorter fragmentation and procedural times”


Dr. Sero Andonian McGill University Health Center, Dept. Of Urology, Montreal, Canada


MoLEP - The New Generation of HoLEP MOSESTM Laser Enucleation of the Prostate

Improved enucleation efficiency

Leverage the power of the MOSES P120H for a more efficient tissue removal and 20% increase in enucleation rate (gr/min). Enjoy the advantages of improved intraoperative vision and cleaner dissection of the capsular plane4.

Better hemostasis

The unique pulse reshaping results in improved hemostasis, providing you with higher visibility during the procedure and bleeding control5,6.

Fiber durability and handling

Initial experiences with the MOSES technology indicate that the proprietary MOSES fibers are durable and show minimal degradation. This may indicate reduced burn back compared to regular mode of operation, resulting in a continuous procedure with minimal interruptions7.


“The MOSES technology has great potential in improving the efficiency of enucleation procedures and also enabling a faster learning curve. In my initial clinical experience, I found that there was a smoother cutting effect, excellent hemostasis and improved visibility. Additionally, the enhanced vapor bubble significantly assists in separating the adenoma from the capsule, resulting in better orientation in the plane.”


Prof. Ivano Vavassori, Azienda Ospedaliera Ospedale Treviglio Caravaggio, Italy


MOSES Vaporization – Acceleration in hand

Higher Vaporization rate and efficiency

The MOSES technology shows superior vaporization rate and efficiency
compared to regular pulse, indicating potential reduction in procedure time7.

Improved coagulation

Control hemostasis and keep bleeding minimal with the advanced pulse reshaping
and customized dual pedal5,6.

Enhanced fiber control

Xpeeda™ D/S/L side firing fiber is designed to deliver increased energy transmission9 and enables work in full
contact mode without causing deep tissue charring7.


“I have noticed significant difference when working with MOSES for vaporization. The vaporization rate was better and I found a smoother vaporization plane. I am looking forward to further exploring the potential benefits of the MOSES technology in BPH treatments.”


Dr. Fernando Gomez Sancha, Clinica Centro Madrid, Spain


References

  1. Elhilali et al. Moses technology in a stone simulator.Can Urol Assoc J. 2018 Apr;12(4):127-130. doi: 10.5489/ cuaj.4797. Epub 2017 Dec 22
  2. Andonian et al. Double-blinded Prospective Randomized Clinical Trial Comparing Moses and Regular Modes of Holmium Laser Lithotripsy: Preliminary Results. Podium presentation at EAU 2018
  3. Elhilali M., Badaan S., Ibrahim A., Andonian S. Use of Moses Pulse Modulation Technology to Improve Holmium Laser Lithotripsy Outcomes: A preclinical study. Journal of Endourology (June, 2017)
  4. Mark Cynk, Holmium Laser Enucleation of the Prostate is More Efficient with More Laser Power, abstract #MP7- 01, Moderated Poster Session 7: BPH/LUTS, WCE 2016
  5. Beaghler M, Leo M, Gass J, March J, Sandoval S, et al. (2017) Initial Experience with New High Powered 120 W Holmium for Vaporization of the Prostate. Urol Nephrol Open Access J 4(2): 00119. DOI: 10.15406/ unoaj.2017.04.00119
  6. Yehudit Kraizer, Shadie Badaan, Moshe Elazar, Haim Epshtein, Uri Shpolansky: Perfused bladder model for simulation of hemostasis control using holmium laser. WCE poster 2014
  7. Bench test results may not necessarily be indicative of clinical performance

PB-2008020 rev A

Get More Info